Stock Watch: Core Business Drags As Roche Disappoints And Sanofi Reclassifies
Q1 Earnings Highlight Plight Of Core Pharmaceutical Businesses
After the volatility of pandemic-related sales, investor and analyst attention turned to pharma’s core businesses. With exclusivity losses weighing on those large components of pharma, Sanofi’s reclassification may bring some unwelcome attention.
